Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Yazmin OdiaCarl J KoschmannNicholas A VitanzaPeter de BlankDolly AguileraJeffrey AllenDoured DaghistaniMatthew HallZiad KhatibCassie N KlineTobey J MacDonaldSabine MuellerShamia L FaisonJoshua E AllenOdin J NadererSamuel C RamageRohinton S TaraporeSusan Lynne McGovernSoumen KhatuaWafik ZakySharon L GardnerPublished in: Neuro-oncology (2024)
ONC201 given D1D2 was well tolerated at all DLs and associated with greater AUC0-48.